GEA
CTIC

Glen Eagle Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Glen Eagle Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250
Closed -$538 – 1013
2020
Q3 		$538 Hold
250
– – ﹤0.01% 880
2020
Q2 		$290 Hold
250
– – ﹤0.01% 883
2020
Q1 		$230 Hold
250
– – ﹤0.01% 826
2019
Q4 		$395 Buy
250
+240
+2,400% +$227 ﹤0.01% 864
2019
Q3 		$8 Hold
10
– – ﹤0.01% 820
2019
Q2 		$9 Hold
10
– – ﹤0.01% 795
2019
Q1 		$10 Hold
10
– – ﹤0.01% 738
2018
Q4 		$7 Hold
10
– – ﹤0.01% 720
2018
Q3 		$22 Hold
10
– – ﹤0.01% 710
2018
Q2 		$50 Hold
10
– – ﹤0.01% 687
2018
Q1 		$39 Hold
10
– – ﹤0.01% 678
2017
Q4 		$27 Hold
10
– – ﹤0.01% 639
2017
Q3 		$32 Buy
+10
New +$33 ﹤0.01% 632

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Glen Eagle Advisors's CTIC Position: Q4 2020 in Review

Glen Eagle Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2020, closing a stake of 250 shares — an estimated $538 sold.

Glen Eagle Advisors first reported a position in CTIC in Q3 2017 and held it in 13 quarters. The position peaked at $538 in Q3 2020. 62 funds tracked by Wall St. Rank hold CTIC as of Q4 2020.

  • Glen Eagle Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2020 after selling out during the quarter.
  • Glen Eagle Advisors sold 250 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2020, an estimated $538.
  • Glen Eagle Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2017 and held it in 13 quarters.
  • Glen Eagle Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $538 in Q3 2020.
  • 62 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2020.

Based on Glen Eagle Advisors's 13F filing for Q4 2020, filed 13 Aug 2024.